J Neurogastroenterol Motil  
Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker
Hideki Mori1 and Hidekazu Suzuki2*
1Department of Gastroenterology, National Hospital Organization Tokyo Medical Center, Tokyo, Japan; and 2Fellowship Training Center and Medical Education Center, Keio University School of Medicine, Tokyo, Japan
Correspondence to: Hidekazu Suzuki, MD, PhD, FACG, AGAF, RFF
Fellowship Training Center and Medical Education Center, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
Tel: +81-3-5363-3914, Fax: +81-3-5363-3967, E-mail: hsuzuki.a6@keio.jp
Received: August 7, 2018; Revised: September 27, 2018; Accepted: October 25, 2018; Published online: November 20, 2018.
© The Korean Society of Neurogastroenterology and Motility. All rights reserved.

cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Proton pump inhibitors are commonly utilized for the treatment of gastric acid-related conditions, such as gastroesophageal reflux disease, peptic ulcer disease, and Helicobacter pylori infection, and for the prevention of low-dose aspirin or nonsteroidal anti-inflammatory drug associated peptic ulcers. Vonoprazan is a first-in-class potassium-competitive acid blocker, which has distinct advantages compared to other conventional proton pump inhibitors in terms of the rate and effectiveness at which gastric acid suppression occurs. Due to its strong gastric acid suppression capabilities, vonoprazan serves as an effective drug for the treatment of gastroesophageal reflux disease and H. pylori infection.
Keywords: Gastroesophageal reflux; Helicobacter pylori; Peptic ulcer; Potassium; Proton pump inhibitors

This Article



Aims and Scope